News | March 30, 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India
Executes the first project for developing and manufacturing a novel anticancer mAb
Executes the first project for developing and manufacturing a novel anticancer mAb
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
Subscribe To Our Newsletter & Stay Updated
